Table 2 HIV-1 co-receptor usage and its associated influence factors
Treatment-naïve group N = 114 | ART group N = 45 | ||||
|---|---|---|---|---|---|
R5 co-receptor usage utilization | X4 co-receptor usage utilization | R5co-receptor usage utilization | X4 co-receptor usage utilization | ||
CD4+T count (cells/μl) | |||||
CD4 < 100 | 8(66.7%) | 4 (33.3%) | 6(28.6%) | 15(71.4%) | p = 0.007 |
100 = < CD4 < 200 | 13(72.2%) | 5 (27.8%) | 5(45.5%) | 6 (54.5%) | |
CD4 > = 200 | 78(92.9%) | 6(7.1%) | 9(84.6%) | 2 (15.4%) | |
VL | |||||
VL(log10) < 4 | 18(90.0%) | 2(10.0%) | 0 11(68.7%) | 7(100.0%) | |
4 = < VL(log10) = < 5 | 43(89.6%) | 5(10.4%) | 11(50.0%) | 5(31.3%) | p < 0.0001 |
VL(log10) > 5 | 40(82.6%) | 6(17.4%) | 11(50.0%) | ||
Therapeutic regimen | |||||
AZT+DDI+NVP | 9(40.9%) | 13 (59.1%) | p = 0.30 | ||
D4T+DDI+NVP | 13(56.5%) | 10 (43.5%) | |||
Treatment time (months) | |||||
< 18 | 5(55.6%) | 4 (44.4%) | P = 0.88 | ||
18-30 | 10(45.5%) | 12 (54.5%) | |||
>= 30 | 7(50.0%) | 7 (50.0%) | |||